amikacin (Arikayce)

following a resubmission considered under the orphan medicine process:

amikacin liposomal nebuliser dispersion (Arikayce®) is accepted for use within NHSScotland.

Indication under review: Treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

The addition of amikacin liposomal nebuliser dispersion to standard oral guideline-based therapy for MAC NTM lung infections significantly increased the proportion of patients achieving sputum culture conversion at 6 months and post-treatment at 3 months.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.